We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Middleware Boosts Efficiency in Lab Automation

By LabMedica International staff writers
Posted on 03 May 2012
New middleware for clinical chemistry, microbiology, and molecular biology labs improves laboratory efficiency, compliance, and quality control.

Dubbed Halia, the middleware utilizes a rule-based engine to deliver all-round control over laboratory workflow, and sample processing. More...
The new interface provides a complete web-based lab computerization system, allowing central management and connection of all analyzers through a single interface on any workstation.

Halia’s user-configurable rule-based engine enables autoverification, sample routing, and real-time clinical data capture and management for greater quality control. By supporting open automation systems and addressing issues such as regulatory compliance, workforce reductions, and enhanced quality control, Halia effectively meets the challenges facing lab managers.

Halia instrument middleware from NoemaLife (Bologna, Italy), a European provider of clinical and hospital software solutions, provides a complete lab computerization solution. Halia also provides detailed real-time data on total turnaround time (TAT)–a key performance indicator in large laboratories striving to increase throughput. Halia permits central management of all the pre-analysis, analysis, and post analysis instruments found in a modern clinical lab.

If a Laboratory Information System/Laboratory Information Management System (LIS/LIMS system) goes down, Halia’s LIS/LIMS backup module allows manual input of sample information so that analysis can continue. Manual samples are then matched to LIS/LIMS data once the connection is restored.

Andrea Chiapponi, managing director of NoemaLife SpA, commented, "In addition to laboratories looking for open middleware which is vendor independent, Halia will be of interest to IVD device vendors wanting to create turnkey solutions which include maximum LIS/LIMS connectivity. Halia’s vendor-independence also enables merging of laboratories and even hospitalswith different LIS/LIMS solutions into a seamless wide area network. For example, Halia can manage re-tests on different analyzers deployed in separate labs and coordinate specimen storage information relating to multiple locations."

Related Links:
NoemaLife



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
hCG Whole Blood Pregnancy Test
VEDALAB hCG-CHECK-1
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.